Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-122 + Nivolumab in Advanced HCC
NCT02859324Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Sep 2016
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of avadomide in hepatocellular carcinoma (HCC), sponsored by Celgene Corporation. Started Sep 2016; status: completed.
02
Drugs
avadomide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02859324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02859324.